Research map: Blinding Integrity and Psychedelic Drug Trials—Reply

Back to the article

Papers in this map

  1. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression · Balázs Szigeti · 2024 · 84 citations · Cited by this paper
  2. Optimizing Study Design for Clinically Useful Peripheral Molecular Biomarker Discovery in Psychiatry · 2026 · Related
  3. Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research · Roger S. McIntyre · 2025 · 26 citations · Cited by this paper
  4. Error in Table · 2026 · Related
  5. Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions · Zachary J. Williams · 2026 · 18 citations · Cited by this paper
  6. Medication and Procedural Abortion and Risk of Psychotropic Medication Use · 2026 · Related
  7. GH001 vs Placebo in Patients With Treatment-Resistant Depression · Wiesław Jerzy Cubała · 2026 · 12 citations · Cited by this paper
  8. Assessing Drug Efficacy After Multiple Negative Trials—Gepirone’s Journey Through the FDA · 2026 · Related
  9. Blinding Integrity in Psychedelic Randomized Clinical Trials · Diana K. Orsini · 2026 · 11 citations · Cited by this paper
  10. Electroencephalography Microstates—A Biomarker for Psychosis? · 2026 · Related
  11. Deconstructing Social Functioning in Psychosis Risk—From Prediction to Recovery · 2026 · Related
  12. Confounding and Circularity in Actigraphy Prediction · 2026 · Related

Source: OpenAlex (CC0)